Vericel Corporation (VCEL) Dividend History

Vericel Corporation (VCEL) is a biotechnology company specializing in the development and commercialization of autologous cell therapy products for the treatment of sports-related injuries, including cartilage and tendon repair. The company focuses on regenerative medicine technologies aimed at improving patient outcomes in musculoskeletal conditions.

64 Sidney St., Cambridge, MA, 02139
Phone: (734) 930-5555

Dividend History

Vericel Corporation currently does not pay dividends

Company News

Vericel Reports Second Quarter 2024 Financial Results

Vericel Corporation reported strong financial results for the second quarter of 2024, with record revenue, MACI revenue growth, and significant margin expansion. The company also provided an update on the progress of its NexoBrid launch and raised its full-year profitability guidance.

GlobeNewswire Inc.
Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06%

The global regenerative medicine market is expected to grow from $31.90 billion in 2023 to $349.93 billion by 2033, driven by advancements in cell therapy, stem cell therapies, and tissue engineering. The musculoskeletal disorders segment is the fastest-growing application area.

GlobeNewswire Inc.

Featured Companies: ABBV BLUE JNJ PFE RCKT
Vericel corp chief legal officer sells $782,700 in company stock - Investing.com

Vericel Corp's Chief Legal Officer, Sean C. Flynn, has sold $782,700 worth of company stock as part of a prearranged trading plan. The transaction comes amid the company's strong financial performance and positive analyst coverage.

Investing.com
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

GlobeNewswire Inc.
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 07:31:54 UTC